TP53 and neoplasm: Both the traditional tumor suppressor mechanism of P53 (cell cycle arrest, etc.) and the non-traditional tumor suppressor mechanism (promoting ferroptosis, etc.) are sufficient to make P53 the focus of targeted drug development.